Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CF2105
- Development stage
- Preclinical
- Lead developer
- Zhongke CELFULL
- Administration
- Topical
01
Overview
CF2105 is a skincare product currently in the product development stage, developed by Zhongke CELFULL Mitochondrial Medicine. It is specifically designed for anti-wrinkle applications, leveraging the company's focus on mitochondrial medicine to address signs of skin aging. While the specific active ingredients and molecular targets have not been publicly disclosed, the product is part of a broader pipeline that applies mitochondrial science to therapeutic, nutraceutical, and cosmetic health. As a skincare candidate, it is intended for topical application to improve skin texture and reduce the appearance of wrinkles.
Beyond the preview
Go deeper on CF2105.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CF2105.